findmyKOL
Clinical trialNCT00842088CompletedPhase 1/PHASE2Interventional

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

SponsorHemaQuest Pharmaceuticals Inc.Enrollment24Sickle Cell Disease
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to assess the safety and tolerability of HQK-1001 administered for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Jamaica
  • University of the West Indies, Mona

    Kingston, Mona, Jamaica

United States
  • Trialogic Research

    Madison, Alabama, United States

  • Children'S Hospital and Research Center at Oakland

    Oakland, California, United States

  • Century Clinical Research, Inc.

    Daytona Beach, Florida, United States

  • Medical College of Georgia

    Augusta, Georgia, United States

  • University of Illinois at Chicago

    Chicago, Illinois, United States

  • Johns Hopkins School of Medicine

    Baltimore, Maryland, United States

  • Unc Comprehensive Sickle Cell Program

    Chapel Hill, North Carolina, United States

  • Texas Children'S Cancer Center and Hematology Service

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

HQK-1001Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2009
Primary completion
31 Jul 2010
Completion
—
Last update posted
1 Aug 2011
Registered enrollment
24
Registry id
NCT00842088
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.